+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Compound heterozygotes for a novel mutation, apo E1 Nagoya (Arg142Ser) and Apo E2 (Arg158Cys), with severe type III hyperlipoproteinemia and familial hypercholesterolemia

Compound heterozygotes for a novel mutation, apo E1 Nagoya (Arg142Ser) and Apo E2 (Arg158Cys), with severe type III hyperlipoproteinemia and familial hypercholesterolemia

Journal of Atherosclerosis and Thrombosis 21(9): 983-988

A patient with severe type III hyperlipoproteinemia and familial hypercholesterolemia (FH) was previously reported (Metabolism, 44,1995:460-465). In the current study, the patient's apolipoprotein (apo) E gene was analyzed. An apo E isoform analysis was performed using isoelectric focusing and immunoblotting. In addition, after DNA preparation, a restriction fragment length polymorphism analysis and DNA sequence analysis were performed. The patient's apo E phenotype was E2/E1, and the genotype was ε2/ε2. The sequence analysis of the patient's DNA revealed a new variant of apo E, which involves a single substitution of one serine (AGC) for one arginine (CGC) at position 142, thereby adding one negatively charged unit to apo E2. Therefore, the patient was compound heterozygous for apo E1 (Arg142Ser) and apo E2 (Arg158Cys). A novel mutation, apo E1 Nagoya (Arg142Ser) in a patient with severe type III hyperlipoproteinemia with heterozygous FH was characterized. Since the presence of arginine at the amino acid residue 142 of apo E is considered to play an important role in binding to LDL receptors, the mutation apo E1 Nagoya (Arg142Ser) likely contributed to the expression of severe type III hyperlipoproteinemia in this patient.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 052269113

Download citation: RISBibTeXText

PMID: 24953047

Related references

Compound heterozygotes for familial defective apo B-100 (FDB) and familial hypercholesterolemia (FH). Atherosclerosis 109(1-2): 206-207, 1994

Diagnosis and therapy of familial hyper- -lipoproteinemia (familial hypercholesterolemia or familial hyperlipoproteinemia of type II). Recenti Progressi in Medicina 51(5): 420-437, 1971

Dextran sulfate cellulose ldl affinity apheresis in the treatment of severe familial hypercholesterolemia and non familial hyperlipoproteinemia a clinical report on twelve cases. Gotto, A M Jr , Et Al (Ed ) Treatment Of Severe Hypercholesterolemia in The Prevention Of Coronary Heart Disease; 2nd International Symposium, Munich, West Germany, June 29-30, 1989 Ix+274p S Karger Ag: Basel, Switzerland; New York, New York, Usa Illus 253-267, 1990

Current treatment of type II familial hyperlipoproteinemia (essential familial hypercholesterolemia). University of Michigan Medical Center Journal 34(4): 197-201, 1968

Long term survival in homozygotes and compound heterozygotes for familial hypercholesterolemia treated with LDL-apheresis. Circulation 96(8 Suppl. ): I734, 10/21/97, 1997

Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. Journal of Clinical Investigation 53(5): 1237-1249, 1974

Inborn errors and lipid metabolism. XXV. Familial hyperlipoproteinemia of the type 3--detection of heterozygotes. Casopis Lekaru Ceskych 111(8): 192-195, 1972

Expression of Type Iii Hyperlipoproteinemia in Apolipoprotein E2 (Arg158Cys) Homozygotes Is Associated With Hyperinsulinemia. Arteriosclerosis, Thrombosis, and Vascular Biology 22(2): 294-299, 2002

Combined familial hypercholesterolemia and type III hyperlipoproteinemia. Harefuah 106(12): 565-566, 1984

Changes in ultracentrifugally separated plasma lipoprotein subfractions in patients with polygenic hypercholesterolemia, familial combined hyperlipoproteinemia, and familial hypercholesterolemia after treatment with atorvastatin. Journal of Clinical Lipidology 9(2): 210-216, 2016

Migratory polyarthritis in familial hypercholesterolemia (type II hyperlipoproteinemia). Arthritis and Rheumatism 11(3): 385-393, 1968

Migratory polyarthritis in familial hypercholesterolemia (type IIa hyperlipoproteinemia). Indian Journal of Pediatrics 77(3): 329-331, 2010

Aortocoronary bypass surgery in an 18 year-old woman with severe hypercholesterolemia (familial hyperlipoproteinemia IIa, homozygote). Kokyu to Junkan. Respiration and Circulation 28(10): 1183-1189, 1980

Heterozygous familial hypercholesterolemia: a new point-mutation (1372del2) in the LDL-receptor gene which causes severe hypercholesterolemia. Human Mutation 14(4): 357, 1999

Coexisting type III hyperlipoproteinemia and familial hypercholesterolemia: a case report. Metabolism: Clinical and Experimental 44(4): 460-465, 1995